EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of Colonic Polyposis in a Woman With Chronic Myeloid Leukemia Treated With Dasatinib

Guido Pelaez iD, Behram Suha Yildiz, Mert Candan, Mohammad Ismail, Francesca Vacca iD, Marianna B Ruzinova iD, Samuel Ballentine iD, Kathleen Byrnes iD, Armin Ghobadi iD

Case Reports in Hematology · 2026-01 · 2026 (1)

DOI: 10.1155/crh/4605635 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Case Reports in Hematology, online erschienen am 21.04.2026. Verfasst von Guido Pelaez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA, wustl.edu. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Chronic myeloid leukemia (CML) is a hematopoietic malignancy driven by constitutive tyrosine kinase activity. Dasatinib, a second‐generation (2G) tyrosine kinase inhibitor (TKI), is a preferred treatment due to its superior, durable, and rapid response rates. While dasatinib has known gastrointestinal (GI) side effects, colonic polyposis is a rare complication, not well described in the literature. Case Presentation Upon routine colonoscopy, a 66‐year‐old woman with chronic‐phase CML was incidentally discovered to have asymptomatic colonic polyposis after 11 months of dasatinib therapy. Histopathology revealed reactive inflammatory changes without evidence of dysplasia or neoplasia. The polyposis resolved completely after cessation of dasatinib.

Conclusion

The mechanism behind dasatinib‐induced polyposis is unclear. We hypothesize a role of dasatinib’s differential inhibition of multiple kinase pathways, regulatory T cells, and STAT5 signaling in the intestinal epithelium, causing an unregulated inflammatory state. This case underscores the need for awareness of this rare adverse effect and further research into its pathogenesis.

Schlagwörter

Stichwörter der Autor:innen

case reportcolondasatinibleukemiapolypstyrosine kinase inhibitor

Autor:innen und Institutionen

  • Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA, wustl.edu.
  • Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey, istanbul.edu.tr.
  • Department of Medicine, Division of Gastroenterology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA, wustl.edu.
  • Department of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA, wustl.edu.
  • Department of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA, wustl.edu.

ORCID-Profile: Guido Pelaez, Francesca Vacca, Marianna B Ruzinova, Samuel Ballentine, Kathleen Byrnes, Armin Ghobadi

Zitieren

APA

Pelaez, G., Yildiz, B. S., Candan, M., Ismail, M., Vacca, F., Ruzinova, M. B., Ballentine, S., Byrnes, K., & Ghobadi, A. (2026). Development of Colonic Polyposis in a Woman With Chronic Myeloid Leukemia Treated With Dasatinib. Case Reports in Hematology, 2026(1). https://doi.org/10.1155/crh/4605635

Vancouver

Pelaez G, Yildiz BS, Candan M, Ismail M, Vacca F, Ruzinova MB, et al. Development of Colonic Polyposis in a Woman With Chronic Myeloid Leukemia Treated With Dasatinib. Case Reports in Hematology. 2026;2026(1). doi:10.1155/crh/4605635

BibTeX
@article{Pelaez2026,
  author = {Pelaez, Guido and Yildiz, Behram Suha and Candan, Mert and Ismail, Mohammad and Vacca, Francesca and Ruzinova, Marianna B and Ballentine, Samuel and Byrnes, Kathleen and Ghobadi, Armin},
  title = {Development of Colonic Polyposis in a Woman With Chronic Myeloid Leukemia Treated With Dasatinib},
  journal = {Case Reports in Hematology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crh/4605635}
}
Kostenlos starten →